AGER and early-onset autosomal dominant Alzheimer disease: Indeed, although trials in patients with mild Alzheimer’s disease did not support clinical efficacy of azeliragon (TTP448, vTv Therapeutics, High Point, NC, USA), an inhibitor of RAGE-amyloid β protein interactions, no obvious safety issues were associated with its use (5 mg orally once daily for 18 months) in human patients40–42.